Seattle's small molecule tyrosine kinase inhibitor tucatinib key phase 3 trial reaches primary and secondary endpoints

today, Seattle Genetics(http://announced that its HER-specific oral small molecule tyrosine kinase inhibitor tucatinib, in the treatment of pre-local advanced or metastatic HER2-positive breast cancer patients in the critical stage 3trial(http://HER2CLIMB, reached the primary and critical secondary endpoint of the trialAbout Tucatinib
Tucatinib is an oral tyrosine kinase inhibitor that is highly selective for HER2, but has no significant inhibition of EGFR in the same human epidermal growth factor receptor familyPrevious studies have shown anti-cancer activity, both as a monotherapy and in combination with chemotherapy and other HER2-targeteddrug(http://Previously, the U.SFDA(http://has granted tucatinib orphan drug eligibility for the treatment of breast cancer patients with brain metastatic tumorsA total of 612 patients participated in a Phase 3 clinical trial called HER2CLIMB The trial was a key clinical study in a randomized, double-blind, active control group designed to compare the efficacy and safety of tucatinib's combined standard therapeutic drugs teratozumab and capecitabine, compared to qutozumab and carpedamine, in patients with advanced local non-resection or metastatic HER2 breast cancer 　　Patients involved in the trial have been treated with hydroquation, pertuzumab and ado-trastuzumab emtansine (T-DM1), and 47% of patients with brain metastatic tumors 　　The results showed that the combination of combination therapy added to tucatinib significantly improved the patient's progressionless lifespan (PFS), reducing the patient's risk of disease progression or death by 46% compared to the combination therapy of trastuzumab and capecitabine, reaching the main endpoint of the trial 　　In addition, triple therapy improved the total survival (OS) of patients and reduced the risk of death by 34 percent compared to the combination of trastuzumab and capecitabine In patients with brain metastasis, triple therapy also showed excellent PFS, reducing the risk of disease progression or death by 52% in such patients, reaching a critical secondary endpoint of the trial